Lysosomal Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • M&A

Lysosomal Therapeutics General Information

Description

Developer of therapies designed for patients with severe neurological diseases affecting movement, cognition and general health. The company is dedicated to innovative, research and development in the field of neurodegeneration and leverages the genetically and clinically validated link between lysosomal disorders and neurodegenerative diseases to establish a unique and effective platform for novel drug discovery, enabling physicians to treat a disease like Parkinson.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 19 Blackstone Street
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 19 Blackstone Street
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lysosomal Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-Oct-2020 Completed Generating Revenue
5. Later Stage VC 07-Nov-2019 Completed Generating Revenue
4. Later Stage VC (Series A) 13-Jan-2017 Completed Product Development
3. Merger/Acquisition 09-Jan-2017 Cancelled Product Development
2. Grant 05-Dec-2014 $230K $4.8M Completed Product Development
1. Seed Round 30-Apr-2014 $4.8M $4.8M Completed Product Development
To view Lysosomal Therapeutics’s complete valuation and funding history, request access »

Lysosomal Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Lysosomal Therapeutics’s complete cap table history, request access »

Lysosomal Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapies designed for patients with severe neurological diseases affecting movement, cognition and general
Drug Discovery
Cambridge, MA
12 As of 2020

New York, NY
 

Framingham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lysosomal Therapeutics Competitors (23)

One of Lysosomal Therapeutics’s 23 competitors is Akelos, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akelos Venture Capital-Backed New York, NY
Alzheon Venture Capital-Backed Framingham, MA
Cerecin Venture Capital-Backed Broomfield, CO
Compass Therapeutics Formerly VC-backed Boston, MA
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
You’re viewing 5 of 23 competitors. Get the full list »

Lysosomal Therapeutics Patents

Lysosomal Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2019126776-A1 Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof Inactive 21-Dec-2017
JP-2021506920-A Crystalline substituted cyclohexylpyrazolo [1,5-a] pyrimidinylcarboxamide compounds and their therapeutic use Inactive 21-Dec-2017
EP-3452455-A1 Substituted imdazo[1,2- ]pyridines, substituted imidazo[1,2- ]pyrazines, related compounds, and their use in the treatment of medical disorders Inactive 05-May-2016
EP-3452455-A4 Substituted imdazo[1,2- ]pyridines, substituted imidazo[1,2- ]pyrazines, related compounds, and their use in the treatment of medical disorders Inactive 05-May-2016
WO-2017192931-A1 Substituted imdazo[1,2-α]pyridines, substituted imidazo[1,2-α]pyrazines, related compounds, and their use in the treatment of medical disorders Inactive 05-May-2016 C07D471/04
To view Lysosomal Therapeutics’s complete patent history, request access »

Lysosomal Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lysosomal Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atlas Venture Venture Capital Minority
Gray Ventures Venture Capital Minority
Hatteras Venture Partners Venture Capital Minority
Lilly Ventures Corporate Venture Capital Minority
Mass General Brigham Ventures Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Lysosomal Therapeutics FAQs

  • When was Lysosomal Therapeutics founded?

    Lysosomal Therapeutics was founded in 2011.

  • Where is Lysosomal Therapeutics headquartered?

    Lysosomal Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Lysosomal Therapeutics?

    Lysosomal Therapeutics has 12 total employees.

  • What industry is Lysosomal Therapeutics in?

    Lysosomal Therapeutics’s primary industry is Drug Discovery.

  • Is Lysosomal Therapeutics a private or public company?

    Lysosomal Therapeutics is a Private company.

  • What is Lysosomal Therapeutics’s current revenue?

    The current revenue for Lysosomal Therapeutics is .

  • How much funding has Lysosomal Therapeutics raised over time?

    Lysosomal Therapeutics has raised $31.9M.

  • Who are Lysosomal Therapeutics’s investors?

    Atlas Venture, Gray Ventures, Hatteras Venture Partners, Lilly Ventures, and Mass General Brigham Ventures are 5 of 8 investors who have invested in Lysosomal Therapeutics.

  • Who are Lysosomal Therapeutics’s competitors?

    Akelos, Alzheon, Cerecin, Compass Therapeutics, and Aro Biotherapeutics are some of the 23 competitors of Lysosomal Therapeutics.

  • When was Lysosomal Therapeutics acquired?

    Lysosomal Therapeutics was acquired on 01-Oct-2020.

  • Who acquired Lysosomal Therapeutics?

    Lysosomal Therapeutics was acquired by Bial.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process